Alex Dorenbaum, MD

Alex Dorenbaum, M.D.  is the Chief Medical Officer at Reneo Pharmaceutical. He is a board-certified allergist-immunologist with over 25 years of experience in drug development and clinical trials. Alex has expertise in small molecules, biologicals, and vaccines in allergy, HIV/AIDS, pulmonary, immunological, cardiovascular, metabolic (including genetic), and pediatric diseases. He has Management experience including people and program leadership, and business development (US, Europe, Japan). Prior to Reneo, Alex was a Clinical Professor, Pediatrics, Immunology and Allergy at Stanford University School of Medicine, Consultant, Clinical Development at Balance Therapeutics Inc., Chief Medical Officer at Allakos Inc., Senior Consultant at Shire Pharmaceuticals, Chief Medical Officer, Lumena Pharmaceuticals Inc., Group Medical Director US Medical Affairs – Immunology Team at Genentech, Senior Director (and Director), Clinical Development at BioMarin Pharmaceutical Inc., Director, Clinical Development at Chiron Corporation, and Assistant Clinical Professor of Pediatrics at UCSF. Alex received his M.D. from the Universidad Nacional Autónoma de México, and was a Fellow at the Baylor College of Medicine.